AdventHealth on Monday introduced a undertaking with biotechnology firm Berg to attempt to higher tailor therapies for COVID-19 sufferers.
AdventHealth and Berg are kicking off the undertaking as a analysis effort, initially constructing a biobank with knowledge pulled from well being information of AdventHealth sufferers who acquired COVID-19 testing. From there, the teams plan to use Berg’s artificial-intelligence instruments to flag interventions linked with higher outcomes in particular affected person populations, based mostly on such traits as ethnicity or comorbidities.
Altamonte Springs, Fla.-based AdventHealth has examined greater than 250,000 individuals for COVID-19, stated Dr. Steven Smith, senior vice chairman and chief scientific officer at AdventHealth.
“That knowledge actually provides us a possibility,” Smith stated.
AdventHealth and Berg started discussing plans to use the corporate’s precision drugs instruments to check situations like non-alcoholic fatty liver illness and sarcopenia, or age-related skeletal muscle mass loss, in late 2019. Nevertheless, within the wake of the pandemic, the teams determined to start out with a concentrate on COVID-19 as a substitute.
AdventHealth and Berg will not be disclosing monetary particulars of the partnership.
AdventHealth and Berg plan to check whether or not bringing collectively data on previous COVID-19 sufferers’ size of keep, administered drugs, medical historical past and outcomes can produce insights that higher inform and goal remedy plans.
“Why was it that these people, who posed such a excessive threat based mostly on all of the identified parameters, their outcomes had been simply nice?” Niven Narain, Berg’s president and CEO, supplied for example of a analysis query to check. That is what “the AI goes to assist to discriminate.”
AdventHealth and Berg are nonetheless within the first section of their analysis collaboration, which entails gathering demographic, medical historical past, laboratory exams and different scientific knowledge for the biobank, getting ready the info for evaluation, and beginning to develop hypotheses.
The second section of the undertaking entails analyzing that knowledge to find out which COVID-19 interventions had been linked with higher outcomes for which forms of sufferers.
Researchers from AdventHealth and Berg plan to develop decision-support instruments for scientific workers as they discover tendencies in how COVID-19 impacts completely different populations or focused therapies that would assist enhance affected person outcomes, in addition to publicly publish their findings.
Smith stated their plan is to publish findings “as quickly as attainable” after validating them, together with publishing their analysis as preprints.
“We have discovered lots from this pandemic,” Smith stated. “One of many issues we have discovered is to maneuver quicker within the scientific realm.”